



Alaska Medical Assistance DUR Committee Meeting
Friday, September 21, 2018
Frontier Building, 3601 C Street; Room 896
1:00pm
1.800.315.6338, access code 24251#

Agenda

- (1) Introduction of new members
- (2) Review of minutes from April 2018
- (3) Review of agenda
- (4) Comments/Suggestions from Committee members
- (5) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - i. Review of new medications to market from 2017 and 2018
 - b. New Prior Authorizations, Quantity Limits, Edits
 - i. Cambia
 - ii. Eucrisa
 - iii. Viberzi
 - iv. Gabapentin
 - c. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. HP Acthar
 - ii. Re-review Buprenorphine MAT criteria and finalize
- (6) Opioids – Initiatives, Monitoring, and Updates
 - a. Medication Assisted Therapy
 - i. Provider MAT PA Waiver implementation
 - b. Dental analgesia protocol update
- (7) New product review-HCPCS
 - a. Skin substitutes
- (8) Standards of Care
 - a. Multiple Rx written same day for same medication circumventing quantity limits
- (9) Past Intervention Informational Updates
 - a. Responses to ABX with fluconazole letter mailed
- (10) FDA/DEA Updates
 - a. FDA Drug Safety Communications
- (11) FAERS Reports
- (12) Quality Measures
- (13) Trend Reports
- (14) End of Public Meeting

Pharmaceutical Manufacturers wishing to submit unsolicited clinical information may do so via the form found at the link below:

http://dhss.alaska.gov/dhcs/Documents/pdf/Documents/AK_Submission_Request_Form_Pharm_Manufacturers.pdf

Submissions for the September meeting must be received no later than 4pm Alaska local time on Wednesday, September 5, 2018.